# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Extrahepatic bile duct cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 41-50 of 50 results.
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Status: Available
Last Changed: Sep 13, 2019
First Received: Sep 12, 2019
Disease(s): Intrahepatic Cholangiocarcinoma
Intervention(s): derazantinib
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Status: Recruiting
Last Changed: Oct 21, 2019
First Received: Jul 26, 2017
Disease(s): Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Intervention(s): derazantinib
Locations: Mayo Clinic, Phoenix, Arizona, United States
Mayo Clinic, Jacksonville, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Mayo Clinic, Rochester, Minnesota, United States
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
... and 18 other locations.
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Status: Recruiting
Last Changed: Feb 27, 2020
First Received: Jul 01, 2019
Disease(s): Biliary Tract Carcinoma
Intervention(s): Pembrolizumab, Gemcitabine, Cisplatin, Placebo
Locations: University of Alabama at Birmingham Comprehensive Cancer Ctr ( Site 0016), Birmingham, Alabama, United States
UCLA Hematology & Oncology ( Site 0014), Santa Monica, California, United States
University of Colorado Hospital ( Site 0011), Aurora, Colorado, United States
Hartford Hospital ( Site 0057), Hartford, Connecticut, United States
Yale University ( Site 0053), New Haven, Connecticut, United States
... and 90 other locations.
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Recruiting
Last Changed: Feb 25, 2020
First Received: May 07, 2018
Disease(s): Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Intervention(s): XmAb20717
Locations: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
UCLA Hematology-Oncology Clinic (Westwood), Los Angeles, California, United States
University of California San Diego Moores Cancer Center, San Diego, California, United States
University of California San Francisco Medical Center, San Francisco, California, United States
Emory University, Atlanta, Georgia, United States
... and 13 other locations.
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Recruiting
Last Changed: Feb 12, 2020
First Received: Nov 06, 2017
Disease(s): Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma
Intervention(s): CDX-1140, CDX-301, Pembrolizumab
Locations: HonorHealth Research Insititute, Scottsdale, Arizona, United States
Northside Hospital, Inc., Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
... and 7 other locations.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Recruiting
Last Changed: Feb 18, 2020
First Received: Dec 11, 2015
Disease(s): Advanced Cancer
Intervention(s): pembrolizumab
Locations: Call for Information (Investigational Site 0018), Duarte, California, United States
Call for Information (Investigational Site 0202), Los Angeles, California, United States
Call for Information (Investigational Site 0203), Aurora, Colorado, United States
Call for Information (Investigational Site 0015), Orlando, Florida, United States
Call for Information (Investigational Site 0011), Baltimore, Maryland, United States
... and 27 other locations.
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Status: Not yet recruiting
Last Changed: Dec 26, 2019
First Received: Dec 26, 2019
Disease(s): Advanced Biliary Tract Cancer
Intervention(s): Toripalimab plus Lenvatinib
Locations: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, Beijing, China
Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice
Status: Not yet recruiting
Last Changed: Jun 06, 2018
First Received: May 17, 2018
Disease(s): Jaundice, Obstructive, Klatskin Tumor
Intervention(s): PTBD group, ENBD group, EBS group
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Status: Recruiting
Last Changed: May 03, 2019
First Received: Aug 22, 2017
Disease(s): Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
Intervention(s): Durvalumab, Guadecitabine
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction
Status: Recruiting
Last Changed: Feb 20, 2019
First Received: Jan 29, 2019
Disease(s): Bile Duct Obstruction, Extrahepatic, Cancer of the Pancreas, Cancer of the Bile Duct, Biliary Stricture
Intervention(s): Biliary stent
Locations: Groote Schuur Hospital, Cape Town, Western Cape, South Africa